CCM
GRTX

CAAS Capital Management’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

CAAS Capital Management’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-273,210
Closed -$2.41M – 1349
2021
Q1 		$2.41M Buy
273,210
+95,069
+53% +$1.04M 0.03% 553
2020
Q4 		$1.82M Buy
+178,141
New +$1.95M 0.02% 509

Other funds holding GRTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAAS Capital Management's GRTX Position: Q2 2021 in Review

CAAS Capital Management sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q2 2021, closing a stake of 273,210 shares — an estimated $2.41M sold.

CAAS Capital Management first reported a position in GRTX in Q4 2020 and held it in 2 quarters. The position peaked at $2.41M in Q1 2021. 47 funds tracked by Wall St. Rank hold GRTX as of Q2 2021.

  • CAAS Capital Management reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 273,210 Galera Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $2.41M.
  • CAAS Capital Management first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • CAAS Capital Management's Galera Therapeutics, Inc. Common Stock position peaked at $2.41M in Q1 2021.
  • 47 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.